The information on this part of the website is intended only for health care professionals. I am an expert within the meaning of Act No. country xy. I herewith confirm that I am a professional according to this definition.
Unfortunately, as you are not a health care professional we cannot provide you this information.
BioGaia recognizes the importance of clinical trials to establish the properties but more importantly the safety of the probiotics used in its products.
As such, BioGaia has conducted numerous clinical trials on the use of Limosilactobacillus reuteri strains as a food supplement. To date, there have been 266 clinical studies on BioGaia’s human strains of Limosilactobacillus reuteri with approximately 22,634 individuals of all ages (> 70% percent in children). Limosilactobacillus reuteri has proven effective in regulating the bacterial balance in the gut and completely safe for both children and adults. The results of studies have been published in numerous articles in various scientific journals, a testimony to its high relevance.
Although valuable, not all bacteria referred to as probiotics are equal.
Limosilactobacillus reuteri Protectis (DSM 17938) is one of the most well-researched strains of probiotic bacteria available, in particular among infants and children up to three years old. This specific strain has been tested in 179 completed clinical trials with approximately 17,969 individuals, 66 percent of which were children. The use of Limosilactobacillus reuteri Protectis has proven entirely safe, which is particularly important for parents who are looking to supplement a baby’s diet. The results are published in professional journal articles which is further proof of the probiotic’s significance among experts.
